Preliminary results from the first registered pilot trial with maternal spindle transfer to overcome infertility

Costa-Borges, Nuno; Nikitos, Eros; Spath, K; Wells, Dagan; Rink, Klaus; Vasilopoulos, Yannis; Zervomanolakis, I.; Konstantinos, Dimitropoulos; Polyzos, Panagiotis; Grigorakis, Stylianos; Kontopoulos, George; Kostaras, Konstantinos; Psathas, Panagiotis; Calderón, Gloria

doi:10.1016/j.fertnstert.2019.07.1329

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 2017, a PNT was performed on a 34-year-old woman who was infertile for 15 years; the procedure resulted in the woman finally giving birth to a baby [57]. In 2019, MST was performed on nine women under 40 years of age who had several unsuccessful IVF attempts due to embryonic developmental arrest; MST resulted in two pregnancies and one live birth [58]. However, nuclear transfer is still controversial due to insufficient evidence regarding its efficacy and safety for reproduction purposes.…”

Section: Mitochondrial Replacement For Reproductionmentioning

confidence: 99%

Mitochondrial Genetic Drift after Nuclear Transfer in Oocytes

Yamada

Akashi

Ooka

et al. 2020

IJMS

View full text Add to dashboard Cite

Mitochondria are energy-producing intracellular organelles containing their own genetic material in the form of mitochondrial DNA (mtDNA), which codes for proteins and RNAs essential for mitochondrial function. Some mtDNA mutations can cause mitochondria-related diseases. Mitochondrial diseases are a heterogeneous group of inherited disorders with no cure, in which mutated mtDNA is passed from mothers to offspring via maternal egg cytoplasm. Mitochondrial replacement (MR) is a genome transfer technology in which mtDNA carrying disease-related mutations is replaced by presumably disease-free mtDNA. This therapy aims at preventing the transmission of known disease-causing mitochondria to the next generation. Here, a proof of concept for the specific removal or editing of mtDNA disease-related mutations by genome editing is introduced. Although the amount of mtDNA carryover introduced into human oocytes during nuclear transfer is low, the safety of mtDNA heteroplasmy remains a concern. This is particularly true regarding donor-recipient mtDNA mismatch (mtDNA–mtDNA), mtDNA-nuclear DNA (nDNA) mismatch caused by mixing recipient nDNA with donor mtDNA, and mtDNA replicative segregation. These conditions can lead to mtDNA genetic drift and reversion to the original genotype. In this review, we address the current state of knowledge regarding nuclear transplantation for preventing the inheritance of mitochondrial diseases.

show abstract

Section: Mitochondrial Replacement For Reproductionmentioning

confidence: 99%